Genta Incorporated Files Shelf Registration Statement
Friday April 2, 8:00 am ET
BERKELEY HEIGHTS, N.J., April 2 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA - News) announced today that it has filed a Form S-3 shelf registration with the Securities and Exchange Commission (SEC). The shelf registration, when declared effective by the SEC, will allow the company to sell up to 15 million common shares in one or more offerings in the future. Specific terms and prices will be determined at the time of any offering.
ADVERTISEMENT
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy such securities be accepted prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell, nor the solicitation of an offer to buy. Further, there shall be no sale of these securities in any state in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
A written prospectus, when available, meeting the requirements of Section 10 of the Securities Act of 1933, as amended, may be obtained from the company at Two Connell Drive, Berkeley Heights, New Jersey, 07922 Attention: William Keane, CFO.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The company's research platform is anchored by two major programs that center on oligonucleotides (RNA and DNA-based medicines) and small molecules. Genasense(TM) (oblimersen sodium) Injection, the company's lead compound from its oligonucleotide program, is being developed with Aventis and is currently undergoing late-stage, Phase 3 clinical testing. The leading drug in Genta's small molecule program is Ganite® (gallium nitrate injection), which the company is exclusively marketing in the U.S. for treatment of patients with cancer-related hypercalcemia that is resistant to hydration. For more information about Genta, please visit our website at: www.genta.com. |
